LKT Labs

Biochemicals for Life Science Research

(E)-4-Hydroxytamoxifen

(E)-4-Hydroxytamoxifen

Product ID H9712
Cas No. 174592-47-3
Purity ≥97%
Product Unit SizeCostQuantityStock
5 mg $214.10 In stock
10 mg $356.90 In stock
25 mg $743.70 In stock
Bulk Quote

Quicklinks

Description

(E)-4-Hydroxytamoxifen is the less active isomer of 4-hydroxytamoxifen. 4-Hydroxytamoxifen is the active metabolite of tamoxifen, a selective estrogen receptor modulator (SERM) that acts as an agonist or antagonist in various tissues. 4-Hydroxytamoxifen exhibits anticancer chemotherapeutic activity, inducing autophagy and vacuole formation as well as KRAS degradation in various cancer cell lines. In cardiac myocytes, 4-hydroxytamoxifen decreases Ca2+ amplitude, slowing relaxation and decreasing contractility.

Product Info

Cas No.

174592-47-3
Purity

≥97%
Formula

C26H29NO2
Formula Wt.

387.51

IUPAC Name

4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
Appearance

White to off white powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

H9712 MSDS PDF
Info Sheet

H9712 Info Sheet PDF

References

Asp ML, Martindale JJ, Metzger JM. Direct, differential effects of tamoxifen, 4-hydroxytamoxifen, and raloxifene on cardiac myocyte contractility and calcium handling. PLoS One. 2013 Oct 24;8(10):e78768. PMID: 24205315.

Kohli L, Kaza N, Coric T, et al. 4-Hydroxytamoxifen induces autophagic death through K-Ras degradation. Cancer Res. 2013 Jul 15;73(14):4395-405. PMID: 23722551.

Schwartz JA, Zhong L, Deighton-Collins S, et al. Mutations targeted to a predicted helix in the extreme carboxyl-terminal region of the human estrogen receptor-alpha alter its response to estradiol and 4-hydroxytamoxifen. J Biol Chem. 2002 Apr 12;277(15):13202-9. Erratum in: J Biol Chem 2002 Jul 5;277(27):24842. PMID: 11823467.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • E6846

    Erlotinib Hydrochloride

    EGFR inhibitor.

    ≥98%
  • P3441

    PIK-294

    p110δ PI3K inhibitor.

    ≥98%
  • P600006

    RP-6306

    PKMYT1 inhibitor

    ≥98%
  • D0005

    Dabrafenib Mesylate

    B-Raf and c-Raf inhibitor.

    ≥98%
  • C5592

    CNX-774

    BTK inhibitor.

    ≥98%
  • B3209

    Bicalutamide

    AR antagonist.

    ≥98%
  • P6958

    Protopanaxatriol

    Triterpene sapogenin found in species of Panax;...

    ≥95%
  • F4581

    5-Fluorocytosine

    Synthetic antifungal.

    ≥98%
  • L0107

    Lactacystin

    Found in Streptomyces; proteasome inhibitor.

    ≥98%
  • R4132

    RKI-1447

    ROCK1/2 inhibitor.

    ≥98%
  • M5752

    Monastrol

    Pyrimidine derivative; kinesin Eg5 inhibitor.

    ≥95%
  • D3575

    2,5-Di-tert-butyl-4-hydroxyanisole

    BHA derivative; potential Ca2+ ATPase inhibitor...

    ≥98%
  • I0010

    5-(9-Isopropyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine

    Intermediate in the synthesis of purine analogs...

    ≥98%
  • K5606

    Kobe 2602

    Ras inhibitor.

    ≥98%
  • I5206

    INCB 28060 Hydrochloride Hydrate

    c-MET inhibitor.

    ≥98%
  • W4096

    WKYMVM-NH2

    Synthetic peptide; FPRL1 agonist.

    ≥95%
  • S584778

    Sotorasib

    KRAS inhibitor

    ≥99%
  • V344761

    Vitamin K2

    2-methyl-1,4-naphthoquinone derivative

    ≥98%
  • T7033

    Trifluoperazine Dihydrochloride

    Phenothiazine; D1/2 and α1-adrenergic antagoni...

    ≥98%
  • E5217

    β-Endorphin, human

    Endogenous opioid peptide; μOR agonist.

    ≥95%